George Gennaoui, DO
Rheumatology · Dearborn, MINPI 1861928681
Payments from drug & device makers
Across 172 payments — averaging $23.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$691
- Johnson & Johnson$657
- AbbVie$558
- AstraZeneca$411
- Novartis$355
- E.r. Squibb & Sons, L.L.C.$262
- plus $1K from 16 others
What the payments were for
- Food & beverage$4,080100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 25 | $691 |
| Johnson & Johnson | 20 | $657 |
| AbbVie | 30 | $558 |
| AstraZeneca(2 entities) | 14 | $411 |
| Novartis | 18 | $355 |
| E.r. Squibb & Sons, L.L.C. | 9 | $262 |
| GSK | 9 | $174 |
| UCB, Inc. | 8 | $159 |
| Mallinckrodt Hospital Products Inc. | 6 | $125 |
| Pfizer | 5 | $123 |
| Lilly USA, LLC | 4 | $87 |
| Radius Health, Inc. | 5 | $80 |
| Organon | 3 | $72 |
| Aurinia Pharma U.S., Inc. | 3 | $61 |
| Sanofi | 3 | $58 |
| Boehringer Ingelheim | 2 | $45 |
| Fresenius Kabi USA, LLC | 2 | $40 |
| Genentech USA, Inc. | 2 | $39 |
| Sandoz | 1 | $24 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $22 |
| Mylan Institutional Inc. | 1 | $21 |
| Novo Nordisk | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,080 in reported general payments places this provider in the 55th percentile of 195 rheumatology providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Humira(Cf) PenAdalimumab | 22 | $146,794 |
| Orencia ClickjectAbatacept | 13 | $71,326 |
| Xeljanz XrTofacitinib Citrate | 12 | $68,293 |
| Hydroxychloroquine Sulfate | 180 | $9,546 |
| MethotrexateMethotrexate Sodium | 244 | $7,862 |
| Colchicine | 74 | $3,717 |
| Celecoxib | 81 | $3,524 |
| Duloxetine Hcl | 150 | $3,364 |
| Prednisone | 425 | $3,313 |
| Leflunomide | 57 | $3,171 |
| Allopurinol | 139 | $1,780 |
| Tramadol Hcl | 182 | $1,665 |
| Gabapentin | 90 | $1,419 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 40 | $1,238 |
| Febuxostat | 14 | $1,231 |
Paid to pharmacies, not to this prescriber.
Other rheumatology in Dearborn
- Dinesh KhannaAnn Arbor$28M
- Amar MajjhooSaint Clair Shores$9.1M
- Joanne KahlenbergAnn Arbor$6M
- Andrew SulichSaint Clair Shores$3.4M
- Elena SchiopuAnn Arbor$3M
- Ali KarrarGrand Blanc$2.5M
- Joshua JuneLansing$2.3M
- Monika MohanOkemos$1.6M
- Kathleen Maksimowicz McKinnonDetroit$842K
- Roman CzubatyjRochester Hills$764K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.